Annual Report

The report describes Merck's 2025 performance, including $65,011 million in sales and approximately 75,000 employees worldwide. It highlights a climate program targeting 46% reductions in Scope 1 and 2 operational GHG emissions and 30% in Scope 3 emissions by 2030, alongside a 2045 net-zero commitment. The report also details environmental oversight through the EHS Council and continued product launches and approvals, including Keytruda Qlex, Enflonsia, and expanded Winrevair indications.